发明名称
摘要 <p>The present invention provides new compounds with high affinity for adenosine A 2A receptors. It also provides antagonists of adenosine A 2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A 2A receptors signalling pathways could be beneficial such as Alzheimer's disease, Parkinson's disease, attention deficit and hyperactivity disorders (ADHD), Huntington's disease, neuroprotection, schizophrenia, anxiety and pain. The present invention further relates to pharmaceutical compositions containing such new compounds with high affinity for adenosine A 2A receptors and their use for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A 2A receptors could be beneficial.</p>
申请公布号 JP2012515759(A) 申请公布日期 2012.07.12
申请号 JP20110546998 申请日期 2010.01.25
申请人 发明人
分类号 C07D471/04;A61K31/437;A61K31/444;A61K31/4545;A61K31/46;A61K31/4709;A61K31/496;A61K31/5377;A61K31/55;A61P1/16;A61P9/10;A61P21/00;A61P25/00;A61P25/02;A61P25/04;A61P25/16;A61P25/18;A61P25/20;A61P25/28;A61P25/30;A61P27/02;A61P43/00;C07D519/00 主分类号 C07D471/04
代理机构 代理人
主权项
地址